CHM Stock Overview
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Chimeric Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.042 |
| 52 Week Low | AU$0.009 |
| Beta | 1.59 |
| 11 Month Change | 0% |
| 3 Month Change | -37.50% |
| 1 Year Change | -67.74% |
| 33 Year Change | -96.15% |
| 5 Year Change | n/a |
| Change since IPO | -96.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHM | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.9% |
| 1Y | -67.7% | 11.0% | 18.4% |
Return vs Industry: CHM underperformed the Australian Biotechs industry which returned 11% over the past year.
Return vs Market: CHM underperformed the Australian Market which returned 18.4% over the past year.
Price Volatility
| CHM volatility | |
|---|---|
| CHM Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: CHM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CHM's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | n/a | www.chimerictherapeutics.com |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors.
Chimeric Therapeutics Limited Fundamentals Summary
| CHM fundamental statistics | |
|---|---|
| Market cap | AU$8.15m |
| Earnings (TTM) | -AU$12.53m |
| Revenue (TTM) | AU$7.46m |
1.1x
P/S Ratio-0.7x
P/E RatioIs CHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHM income statement (TTM) | |
|---|---|
| Revenue | AU$7.46m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$7.46m |
| Other Expenses | AU$19.99m |
| Earnings | -AU$12.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 100.00% |
| Net Profit Margin | -168.01% |
| Debt/Equity Ratio | 0% |
How did CHM perform over the long term?
See historical performance and comparison